Prevention of Delirium (POD) for older people in hospital - a feasibility study

Conditions

Topic: Generic Health Relevance and Cross Cutting Themes

John Young, John R. Green, Mary Godfrey, Jane Smith, Francine Cheater et al. (20 authors)

Programme Grants for Applied Research2021-03-014 citations

10.3310/pgfar09040

A multicentre, pragmatic, cluster randomised, controlled feasibility trial of the POD system of care

John Young, John Green, Amanda Farrin, Michelle Collinson, Suzanne Hartley et al. (9 authors)

Age and Ageing2020-02-2614 citations

10.1093/ageing/afaa044

Use of the confusion assessment method in multicentre delirium trials: training and standardisation.

Green JR, Smith J, Teale E, Collinson M, Avidan MS, Schmitt EM, Inouye SK, Young J.

2019-04-1521 citations

10.1186/s12877-019-1129-8

Prevention of delirium (POD) for older people in hospital: study protocol for a randomised controlled feasibility trial

John Young, Francine Cheater, Michelle Collinson, Marie Fletcher, Anne Förster et al. (17 authors)

Trials2015-08-0727 citations

10.1186/s13063-015-0847-2

Interventions

Participants are randomised to two groups: 1. POD System of Care: The POD System of Care is a quality improvement, multi-component delirium prevention intervention which will be delive

Study Entry: Registration only

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients aged 65 years or older who do not have delirium when admitted to any elderly care/geriatric medicine or orthopaedic trauma/orthopaedic surgery wards taking part in the study will be assessed and given the opportunity to join.

Exclusion criteria

Exclusion criteria: 1. Patients with prevalent delirium diagnosed by completion of the Confusion Assessment Method 2. Patients with a planned discharged from hospital within 48 hours of admission (established from information provided by the ward staff) 3. Patients where a delirium assessment (i.e. CAM) has not been performed within 24 hours of admission to the ward (for elderly care patients) or pre-operatively (e.g. fracture patients) 4. Patients who have not provided consent or consultee declaration for trial participation within 48 hours of admission to the ward 5. Patients receiving end of life care (because it is unlikely follow-up data will be available for these patients)

Design outcomes

Primary

Measure	Time frame
1. Estimate effectiveness through calculating incidence of delirium within 10 days of hospital admission 2. Estimate cost-effectiveness 3. Assess intervention delivery 4. Estimate recruitment uptake and follow-up rates 5. Assess completeness of follow-up data collection 6. Assess degree of contamination 7. Estimate cost-effectiveness	—

Secondary

Measure	Time frame
1. Number, severity and length of delirium episodes (including persistent delirium at 30 days post admission) 2. Length of stay 3. Death 4. Discharge destination 5. Health outcome as measured by the EQ5D at baseline, 30 days and 3 months 6. Physical and social independence as measured by the NEADL at baseline and 3 months 7. Depression as measured by the Geriatric Depression Scale at 30 days 8. Anxiety as measured by the Clincial Anxiety Scale at 30 days 9. Patient experience as measured by the Patient Reported Experience Measure from the National Audit of Intermediate Care at 30 days 10. Health and social care economic resource as measured by the trial-specific Health Economic resource use questionnaire at 30 days	—

Measure

Time frame

1. Number, severity and length of delirium episodes (including persistent delirium at 30 days post admission) 2. Length of stay 3. Death 4. Discharge destination 5. Health outcome as measured by the EQ5D at baseline, 30 days and 3 months 6. Physical and social independence as measured by the NEADL at baseline and 3 months 7. Depression as measured by the Geriatric Depression Scale at 30 days 8. Anxiety as measured by the Clincial Anxiety Scale at 30 days 9. Patient experience as measured by the Patient Reported Experience Measure from the National Audit of Intermediate Care at 30 days 10. Health and social care economic resource as measured by the trial-specific Health Economic resource use questionnaire at 30 days

—

Countries

England, United Kingdom, Wales

Outcome results

None listed